Anti-B7-H3 antibody-drug conjugate reduced the risk of death by 54% versus topotecan and improved progression-free survival and response rates SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCL

MRI surveillance without prophylactic cranial irradiation improved cognitive failure-free survival and substantially reduced serious treatment-related adverse events SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC). The fin

Phase 3 EVOKE-03/KEYNOTE-D46 reports numerically longer progression-free survival and higher response rates, but no statistically significant PFS or OS benefit SEOUL, Republic of Korea, Sept. 13, 2026 /PRNewswire/ -- Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion

B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates SEOUL, South Korea, Sept. 13, 2026 /PRNewswire/ -- Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or aft

HONG KONG, Sept. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). The study evaluated the company's first-in-class next-generation immuno-oncology therapy, ivonescimab, versus pembrolizumab as

AstraZeneca's Etcamah (camizestrant) has fallen short in a Phase III study testing whether the oral selective oestrogen receptor degrader (SERD) could outperform an aromatase inhibitor when used as an upfront treatment for advanced ER-positive, HER2-negative breast cancer.In the SERENA-4 trial, AstraZeneca said Etcamah plus Pfizer's Ibrance (palbociclib) produced a "numerical improvement" on the primary endpoint of progression-free survival versus anastrozole plus Ibrance, but the difference was

GSK shared detailed Phase III findings of a B7-H3–targeting antibody-drug conjugate (ADC) that is quickly turning into a key candidate in the company's oncology lineup.Risvutatug rezetecan (ris-rez), which is partnered with Hansoh Pharmaceutical Group Co., cut the risk of death by 54% versus topotecan in second-line patients with relapsed small-cell lung cancer (SCLC), according to results from the ARTEMIS-008 study presented this weekend at the World Conference on Lung Cancer (WCLC)."These resu

The platform combines online access, individualized treatment, home delivery, and continued patient support in one connected care experienceWinter Park, FL, Sept. 12, 2026 (GLOBE NEWSWIRE) -- Zenbody RX has launched its telehealth services to introduce a digital care model that makes personalized weight management more convenient while keeping clinical oversight central to the patient experience. Currently focused on GLP-1 medications, the platform connects assessment, provider review, individ

AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers cannot say the medications caused these problems, but the patterns may reveal overlooked signals worth studying.Artificial intelligence is giving researchers a new way to listen to what patients are saying about popular GLP-1 drugs. After analyzing more than 400,000 Reddit posts, a Uni

Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3Roche is de